Björn Bosse

Prolonged release oxycodone–naloxone for treatment of severe restless legs syndrome after failure of previous treatment: a double-blind, randomised, placebo-controlled trial with an open-label extension

Claudia Trenkwalder, Heike Beneš, Ludger Grote et al. · The Lancet Neurology · 2013 · 220 citations

Pain Disorders, Pain Medicine, Prolonged Release Oxycodone–naloxone +10

A randomized, double-blind, active-controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain

Sam H. Ahmedzai, Friedemann Nauck, Gil Bar‐Sela et al. · Palliative Medicine · 2011 · 162 citations · Full text

Pharmacokinetics of concentrated naloxone nasal spray for opioid overdose reversal: Phase I healthy volunteer study

Rebecca McDonald, Ulrike Lorch, Jo Woodward et al. · Addiction · 2017 · 92 citations · Full text

Efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of moderate/severe chronic non-malignant pain: results of a prospectively designed pooled analysis of two randomised, double-blind clinical trials

O. Löwenstein, Petra Leyendecker, Eberhard A. Lux et al. · BMC Clinical Pharmacology · 2010 · 70 citations · Full text

Sleep and Quality of Life Under Prolonged Release Oxycodone/Naloxone for Severe Restless Legs Syndrome: An Analysis of Secondary Efficacy Variables of a Double-Blind, Randomized, Placebo-Controlled Study with an Open-Label Extension

Wolfgang H. Oertel, Yngve Hallström, G. Saletu‐Zyhlarz et al. · CNS Drugs · 2016 · 22 citations · Full text

Secondary Efficacy Variables, Sleep Disorders, Sleep +14